About the Authors

Gail A. Alvares

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Daniel S. Quintana

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Andrew H. Kemp

Affiliations School of Psychology, The University of Sydney, Sydney, New South Wales, Australia, Hospital Universitário, University of São Paulo, São Paulo, Brazil

Anita Van Zwieten

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Bernard W. Balleine

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Ian B. Hickie

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Adam J. Guastella

adam.guastella@sydney.edu.au

Affiliation Brain & Mind Research Institute, The University of Sydney, Sydney, New South Wales, Australia

Competing Interests

Andrew H. Kemp is a PLOS ONE Editorial Board member. Ian B. Hickie is a member of the Medical Advisory Panel for BUPA Health Insurance (Australia) and also a Board Member of Psychosis Australia Trust. From 2012, he is a Commissioner in Australia’s new National Mental Health Commission. He was until January 2012 a director of headspace: the national youth mental health foundation. Professor Hickie was previously the chief executive officer (till 2003) and clinical adviser (till 2006) of beyondblue, an Australian National Depression Initiative. He is supported principally for clinical research in depression and health services and population health initiatives related to anxiety and depression by an NHMRC Australian Medical Research Fellowship (2007–2012). He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of nongovernment organisations and the pharmaceutical industry (including Pfizer, Servier and Astra Zeneca). He has served on advisory boards convened by the pharmaceutical industry in relation to specific antidepressants, including nefazodone, duloxetine and desvenlafaxine. He leads a new investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier but also by other NHMRC funding) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier supported study of major depression and sleep disturbance in primary care settings. In addition to national and international government-based grant bodies, investigator-initiated mental health research at the BMRI, he has been supported by various pharmaceutical manufacturers (including Servier and Pfizer) and not-for-profit entities (including the Heart Foundation, beyondblue and the BUPA Foundation). None of these declared interests alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: GAA DSQ AHK AJG. Performed the experiments: GAA DSQ AVZ. Analyzed the data: GAA DSQ AHK AJG. Wrote the paper: GAA DSQ AHK AVZ BWB IBH AJG. Approved the final version of the paper: GAA DSQ AHK AVZ BWB IBH AJG.